{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:16:28Z","timestamp":1790007388664,"version":"4.0.1"},"reference-count":95,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1097\/fpc.0000000000000393","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T14:28:27Z","timestamp":1576592907000},"page":"34-44","source":"Crossref","is-referenced-by-count":20,"title":["PharmGKB summary: very important pharmacogene information for CACNA1S"],"prefix":"10.1097","volume":"30","author":[{"given":"Katrin","family":"Sangkuhl","sequence":"first","affiliation":[{"name":"Department of Biomedical Data Sciences, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Dirksen","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Alvarellos","sequence":"additional","affiliation":[{"name":"Department of Biomedical Data Sciences, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russ B.","family":"Altman","sequence":"additional","affiliation":[{"name":"Department of Biomedical Data Sciences, Stanford University, Stanford, California"},{"name":"Biomedical Engineering"},{"name":"Genetics"},{"name":"Medicine, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teri E.","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Biomedical Data Sciences, Stanford University, Stanford, California"},{"name":"Medicine, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230911","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/bja\/aev225","article-title":"European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility.","volume":"115","author":"Hopkins","year":"2015","journal-title":"Br J Anaesth"},{"key":"R2-20230911","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13023-015-0310-1","article-title":"Malignant hyperthermia: a review.","volume":"10","author":"Rosenberg","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"R3-20230911","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1097\/00000542-200606000-00008","article-title":"Malignant hyperthermia in japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing.","volume":"104","author":"Ibarra M","year":"2006","journal-title":"Anesthesiology"},{"key":"R4-20230911","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/gim.2013.73","article-title":"ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.","volume":"15","author":"Green","year":"2013","journal-title":"Genet Med"},{"key":"R5-20230911","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/gim.2016.190","article-title":"Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the american college of medical genetics and genomics.","volume":"19","author":"Kalia","year":"2017","journal-title":"Genet Med"},{"key":"R6-20230911","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/practneurol-2017-001677","article-title":"Diverse phenotype of hypokalaemic periodic paralysis within a family.","volume":"18","author":"Chalissery","year":"2018","journal-title":"Pract Neurol"},{"key":"R7-20230911","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1210\/jc.2006-0356","article-title":"Clinical review: thyrotoxic periodic paralysis: a diagnostic challenge.","volume":"91","author":"Kung","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R8-20230911","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1007\/s12630-017-0978-x","article-title":"Idiopathic hyperckemia and malignant hyperthermia susceptibility.","volume":"64","author":"Santos","year":"2017","journal-title":"Can J Anaesth"},{"key":"R9-20230911","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2217\/pgs-2018-0106","article-title":"RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms.","volume":"19","author":"Isackson","year":"2018","journal-title":"Pharmacogenomics"},{"key":"R10-20230911","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1124\/pr.57.4.5","article-title":"International union of pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels.","volume":"57","author":"Catterall","year":"2005","journal-title":"Pharmacol Rev"},{"key":"R11-20230911","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/pr.114.009654","article-title":"The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential.","volume":"67","author":"Zamponi","year":"2015","journal-title":"Pharmacol Rev"},{"key":"R12-20230911","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/380072a0","article-title":"Enhanced dihydropyridine receptor channel activity in the presence of ryanodine receptor.","volume":"380","author":"Nakai","year":"1996","journal-title":"Nature"},{"key":"R13-20230911","doi-asserted-by":"crossref","first-page":"21913","DOI":"10.1074\/jbc.274.31.21913","article-title":"The II-III loop of the skeletal muscle dihydropyridine receptor is responsible for the bi-directional coupling with the ryanodine receptor.","volume":"274","author":"Grabner","year":"1999","journal-title":"J Biol Chem"},{"key":"R14-20230911","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/FPC.0000000000000170","article-title":"Pharmgkb summary: succinylcholine pathway, pharmacokinetics\/pharmacodynamics.","volume":"25","author":"Alvarellos","year":"2015","journal-title":"Pharmacogenet Genomics"},{"key":"R15-20230911","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s40478-016-0392-6","article-title":"Review of ryr1 pathway and associated pathomechanisms.","volume":"4","author":"Witherspoon","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"R16-20230911","doi-asserted-by":"crossref","first-page":"10986","DOI":"10.1073\/pnas.1612441113","article-title":"Stac3 has a direct role in skeletal muscle-type excitation-contraction coupling that is disrupted by a myopathy-causing mutation.","volume":"113","author":"Polster","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R17-20230911","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.biocel.2013.12.001","article-title":"Skeletal muscle excitation-contraction coupling: who are the dancing partners?.","volume":"48","author":"Rebbeck","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"key":"R18-20230911","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1385\/JMN:21:1:35","article-title":"Screening for mutations in the RYR1 gene in families with malignant hyperthermia.","volume":"21","author":"Muniz","year":"2003","journal-title":"J Mol Neurosci"},{"key":"R19-20230911","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00401-016-1656-8","article-title":"Dihydropyridine receptor (DHPR, CACNA1S) congenital myopathy.","volume":"133","author":"Schartner","year":"2017","journal-title":"Acta Neuropathol"},{"key":"R20-20230911","doi-asserted-by":"crossref","first-page":"39193","DOI":"10.1074\/jbc.M006467200","article-title":"Functional embryonic cardiomyocytes after disruption of the L-type alpha1c (cav1.2) calcium channel gene in the mouse.","volume":"275","author":"Seisenberger","year":"2000","journal-title":"J Biol Chem"},{"key":"R21-20230911","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1101\/gr.092841.109","article-title":"The clinseq project: piloting large-scale genome sequencing for research in genomic medicine.","volume":"19","author":"Biesecker","year":"2009","journal-title":"Genome Res"},{"key":"R22-20230911","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/ALN.0b013e3182a8a8e7","article-title":"Using exome data to identify malignant hyperthermia susceptibility mutations.","volume":"119","author":"Gonsalves","year":"2013","journal-title":"Anesthesiology"},{"key":"R23-20230911","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/ALN.0000000000001878","article-title":"Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.","volume":"128","author":"Riazi","year":"2018","journal-title":"Anesthesiology"},{"key":"R25-20230911","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1213\/ANE.0000000000000063","article-title":"DNA testing for malignant hyperthermia: the reality and the dream.","volume":"118","author":"Stowell","year":"2014","journal-title":"Anesth Analg"},{"key":"R26-20230911","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/bja\/aeq243","article-title":"Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group.","volume":"105","author":"Glahn","year":"2010","journal-title":"Br J Anaesth"},{"key":"R27-20230911","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/00000542-199205000-00008","article-title":"Effects of dantrolene on myoplasmic free [ca2+] measured in vivo in patients susceptible to malignant hyperthermia.","volume":"76","author":"Lopez","year":"1992","journal-title":"Anesthesiology"},{"key":"R28-20230911","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1085\/jgp.201711864","article-title":"Voltage modulates halothane-triggered ca2+ release in malignant hyperthermia-susceptible muscle.","volume":"150","author":"Zullo","year":"2018","journal-title":"J Gen Physiol"},{"key":"R29-20230911","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/cpt.1319","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.","volume":"105","author":"Gonsalves","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"R30-20230911","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/gim.2016.87","article-title":"Standardizing terms for clinical pharmacogenetic test results: consensus terms from the clinical pharmacogenetics implementation consortium (CPIC).","volume":"19","author":"Caudle","year":"2017","journal-title":"Genet Med"},{"key":"R31-20230911","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/clpt.2010.279","article-title":"CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network.","volume":"89","author":"Relling","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R32-20230911","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1086\/515454","article-title":"Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle.","volume":"60","author":"Monnier","year":"1997","journal-title":"Am J Hum Genet"},{"key":"R33-20230911","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1086\/515483","article-title":"To fire the train: a second malignant-hyperthermia gene.","volume":"60","author":"Hogan","year":"1997","journal-title":"Am J Hum Genet"},{"key":"R34-20230911","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1034\/j.1399-0004.2001.590306.x","article-title":"Identification of the arg1086his mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a north american family with malignant hyperthermia.","volume":"59","author":"Stewart","year":"2001","journal-title":"Clin Genet"},{"key":"R35-20230911","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/00000542-200211000-00007","article-title":"Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility.","volume":"97","author":"Monnier","year":"2002","journal-title":"Anesthesiology"},{"key":"R36-20230911","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/humu.20231","article-title":"Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility.","volume":"26","author":"Monnier","year":"2005","journal-title":"Hum Mutat"},{"key":"R37-20230911","doi-asserted-by":"crossref","first-page":"C1094","DOI":"10.1152\/ajpcell.00173.2004","article-title":"Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling.","volume":"287","author":"Weiss","year":"2004","journal-title":"Am J Physiol Cell Physiol"},{"key":"R38-20230911","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s12630-010-9314-4","article-title":"A report of fulminant malignant hyperthermia in a patient with a novel mutation of the CACNA1S gene.","volume":"57","author":"Toppin","year":"2010","journal-title":"Can J Anaesth"},{"key":"R39-20230911","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.bja.2018.06.028","article-title":"Genetic epidemiology of malignant hyperthermia in the UK.","volume":"121","author":"Miller","year":"2018","journal-title":"Br J Anaesth"},{"key":"R40-20230911","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/00000542-199404000-00008","article-title":"A clinical grading scale to predict malignant hyperthermia susceptibility.","volume":"80","author":"Larach","year":"1994","journal-title":"Anesthesiology"},{"key":"R41-20230911","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1471-2350-10-104","article-title":"The role of CACNA1S in predisposition to malignant hyperthermia.","volume":"10","author":"Carpenter","year":"2009","journal-title":"BMC Med Genet"},{"key":"R42-20230911","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.nmd.2017.02.008","article-title":"Resequencing array for gene variant detection in malignant hyperthermia and butyrylcholinestherase deficiency.","volume":"27","author":"Levano","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"R43-20230911","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1073\/pnas.1119207109","article-title":"Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type ca2+ channel and the type 1 ryanodine receptor.","volume":"109","author":"Eltit","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R44-20230911","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1097\/ALN.0000000000000610","article-title":"Next-generation sequencing of RYR1 and CACNA1S in malignant hyperthermia and exertional heat illness.","volume":"122","author":"Fiszer","year":"2015","journal-title":"Anesthesiology"},{"key":"R45-20230911","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1213\/ANE.0000000000000421","article-title":"Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the north american malignant hyperthermia registry of the Malignant Hyperthermia Association of the United States.","volume":"119","author":"Larach","year":"2014","journal-title":"Anesth Analg"},{"key":"R46-20230911","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1213\/ANE.0b013e31828a71ff","article-title":"Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the united states.","volume":"116","author":"Brandom","year":"2013","journal-title":"Anesth Analg"},{"key":"R47-20230911","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/ALN.0b013e3182a8a998","article-title":"Exome sequencing reveals novel rare variants in the ryanodine receptor and calcium channel genes in malignant hyperthermia families.","volume":"119","author":"Kim","year":"2013","journal-title":"Anesthesiology"},{"key":"R48-20230911","doi-asserted-by":"crossref","first-page":"C1345","DOI":"10.1152\/ajpcell.00008.2010","article-title":"Identification and functional characterization of malignant hyperthermia mutation T1354S in the outer pore of the cavalpha1s-subunit.","volume":"299","author":"Pirone","year":"2010","journal-title":"Am J Physiol Cell Physiol"},{"key":"R49-20230911","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1007\/s12630-017-0865-5","article-title":"Malignant hyperthermia susceptibility in patients with exertional rhabdomyolysis: a retrospective cohort study and updated systematic review.","volume":"64","author":"Kraeva","year":"2017","journal-title":"Can J Anaesth"},{"key":"R50-20230911","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1399-0004.2010.01493.x","article-title":"Novel missense mutations and unexpected multiple changes of RYR1 gene in 75 malignant hyperthermia families.","volume":"79","author":"Tammaro","year":"2011","journal-title":"Clin Genet"},{"key":"R51-20230911","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0310057X1504300204","article-title":"Analysis of the entire ryanodine receptor type 1 and alpha 1 subunit of the dihydropyridine receptor (CACNA1S) coding regions for variants associated with malignant hyperthermia in australian families.","volume":"43","author":"Gillies","year":"2015","journal-title":"Anaesth Intensive Care"},{"key":"R53-20230911","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/mus.26009","article-title":"Review of the diagnosis and treatment of periodic paralysis.","volume":"57","author":"Statland","year":"2018","journal-title":"Muscle Nerve"},{"key":"R54-20230911","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1085\/jgp.201711923","article-title":"An atypical cav1.1 mutation reveals a common mechanism for hypokalemic periodic paralysis.","volume":"149","author":"Cannon","year":"2017","journal-title":"J Gen Physiol"},{"key":"R55-20230911","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1212\/WNL.53.7.1556","article-title":"Insulin acts in hypokalemic periodic paralysis by reducing inward rectifier K+ current.","volume":"53","author":"Ruff","year":"1999","journal-title":"Neurology"},{"key":"R56-20230911","doi-asserted-by":"crossref","first-page":"9549","DOI":"10.1073\/pnas.97.17.9549","article-title":"Voltage-sensor sodium channel mutations cause hypokalemic periodic paralysis type 2 by enhanced inactivation and reduced current.","volume":"97","author":"Jurkat-Rott","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R57-20230911","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/164_2017_52","article-title":"Sodium channelopathies of skeletal muscle.","volume":"246","author":"Cannon","year":"2018","journal-title":"Handb Exp Pharmacol"},{"key":"R58-20230911","first-page":"374","article-title":"Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNL1A3): genotype\/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 caucasian families.","volume":"56","author":"Elbaz","year":"1995","journal-title":"Am J Hum Genet"},{"key":"R59-20230911","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/jmg.32.1.44","article-title":"Mutation in DHP receptor alpha 1 subunit (CACLN1A3) gene in a dutch family with hypokalaemic periodic paralysis.","volume":"32","author":"Boerman","year":"1995","journal-title":"J Med Genet"},{"key":"R60-20230911","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1442-200x.2000.01214.x","article-title":"Hypokalemic periodic paralysis and mutations in the CACNL1A3 gene: case study in a japanese family.","volume":"42","author":"Wada","year":"2000","journal-title":"Pediatr Int"},{"key":"R61-20230911","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/ndt\/16.5.939","article-title":"Identification of mutations including de novo mutations in korean patients with hypokalaemic periodic paralysis.","volume":"16","author":"Kim","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"R62-20230911","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2169\/internalmedicine.43.218","article-title":"A family of hypokalemic periodic paralysis with CACNA1S gene mutation showing incomplete penetrance in women.","volume":"43","author":"Kawamura","year":"2004","journal-title":"Intern Med"},{"key":"R63-20230911","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00000441-200502000-00003","article-title":"Skeletal muscle dihydropyridine-sensitive calcium channel (CACNA1S) gene mutations in chinese patients with hypokalemic periodic paralysis.","volume":"329","author":"Lin","year":"2005","journal-title":"Am J Med Sci"},{"key":"R64-20230911","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/mus.20825","article-title":"Progressive muscle atrophy with hypokalemic periodic paralysis and calcium channel mutation.","volume":"37","author":"Meyer","year":"2008","journal-title":"Muscle Nerve"},{"key":"R65-20230911","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3346\/jkms.2007.22.6.946","article-title":"The genotype and clinical phenotype of korean patients with familial hypokalemic periodic paralysis.","volume":"22","author":"Kim","year":"2007","journal-title":"J Korean Med Sci"},{"key":"R66-20230911","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MAJ.0b013e31822b430c","article-title":"Genotype and phenotype analysis of patients with sporadic periodic paralysis.","volume":"343","author":"Sung","year":"2012","journal-title":"Am J Med Sci"},{"key":"R67-20230911","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3345\/kjp.2011.54.11.473","article-title":"Hypokalemic periodic paralysis; two different genes responsible for similar clinical manifestations.","volume":"54","author":"Kim","year":"2011","journal-title":"Korean J Pediatr"},{"key":"R68-20230911","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/mus.23460","article-title":"Gender differences in penetrance and phenotype in hypokalemic periodic paralysis.","volume":"47","author":"Ke","year":"2013","journal-title":"Muscle Nerve"},{"key":"R69-20230911","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/mus.24225","article-title":"Cardiac arrhythmias in hypokalemic periodic paralysis: hypokalemia as only cause?.","volume":"50","author":"Stunnenberg","year":"2014","journal-title":"Muscle Nerve"},{"key":"R70-20230911","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/mus.10298","article-title":"Severe prognosis in a large family with hypokalemic periodic paralysis.","volume":"27","author":"Caciotti","year":"2003","journal-title":"Muscle Nerve"},{"key":"R71-20230911","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.nmd.2018.03.006","article-title":"Prevalence and mutation spectrum of skeletal muscle channelopathies in the netherlands.","volume":"28","author":"Stunnenberg","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"R72-20230911","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1172\/JCI66091","article-title":"A calcium channel mutant mouse model of hypokalemic periodic paralysis.","volume":"122","author":"Wu","year":"2012","journal-title":"J Clin Invest"},{"key":"R73-20230911","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00109-005-0638-4","article-title":"Novel CACNA1S mutation causes autosomal dominant hypokalemic periodic paralysis in a chinese family.","volume":"83","author":"Wang","year":"2005","journal-title":"J Mol Med (Berl)"},{"key":"R74-20230911","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.3892\/mmr.2015.4201","article-title":"Mutation analysis of CACNA1S and SCN4A in patients with hypokalemic periodic paralysis.","volume":"12","author":"Wang","year":"2015","journal-title":"Mol Med Rep"},{"key":"R75-20230911","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1471-2490-14-96","article-title":"A rare case of unilateral adrenal hyperplasia accompanied by hypokalaemic periodic paralysis caused by a novel dominant mutation in CACNA1S: features and prognosis after adrenalectomy.","volume":"14","author":"Yang","year":"2014","journal-title":"BMC Urol"},{"key":"R76-20230911","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/jhg.2009.92","article-title":"Novel CACNA1S mutation causes autosomal dominant hypokalemic periodic paralysis in a south american family.","volume":"54","author":"Ke","year":"2009","journal-title":"J Hum Genet"},{"key":"R77-20230911","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jfma.2013.07.007","article-title":"V876E mutation in CACNA1S gene associated with severe hypokalemic periodic paralysis in a chinese woman.","volume":"114","author":"Yang","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"R78-20230911","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/jmg.2008.059766","article-title":"Early onset of hypokalaemic periodic paralysis caused by a novel mutation of the CACNA1S gene.","volume":"45","author":"Chabrier","year":"2008","journal-title":"J Med Genet"},{"key":"R79-20230911","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1399-0004.2012.01951.x","article-title":"Exploring the utility of whole-exome sequencing as a diagnostic tool in a child with atypical episodic muscle weakness.","volume":"83","author":"Hanchard","year":"2013","journal-title":"Clin Genet"},{"key":"R80-20230911","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jns.2011.07.046","article-title":"A novel mutation in the calcium channel gene in a family with hypokalemic periodic paralysis.","volume":"309","author":"Hirano","year":"2011","journal-title":"J Neurol Sci"},{"key":"R81-20230911","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1212\/01.wnl.0000342387.65477.46","article-title":"Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis.","volume":"72","author":"Matthews","year":"2009","journal-title":"Neurology"},{"key":"R82-20230911","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1179\/1743132814Y.0000000440","article-title":"Muscle edema of the lower limb determined by MRI in asian hypokalaemic periodic paralysis patients.","volume":"37","author":"Jia","year":"2015","journal-title":"Neurol Res"},{"key":"R83-20230911","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.nmd.2015.09.006","article-title":"The R900S mutation in CACNA1S associated with hypokalemic periodic paralysis.","volume":"25","author":"Ke","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"R84-20230911","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3346\/jkms.2005.20.1.162","article-title":"A korean family of hypokalemic periodic paralysis with mutation in a voltage-gated calcium channel (R1239G).","volume":"20","author":"Kim","year":"2005","journal-title":"J Korean Med Sci"},{"issue":"Suppl 1","key":"R85-20230911","first-page":"155","article-title":"Myopathy as the first symptom of hypokalemic periodic paralysis\u2013case report of a girl from a polish family with CACNA1S (R1239G) mutation.","volume":"52","author":"Winczewska-Wiktor","year":"2007","journal-title":"Adv Med Sci"},{"key":"R86-20230911","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.1440-1819.2001.00902.x","article-title":"Muscle weakness in a japanese family of arg1239his mutation hypokalemic periodic paralysis.","volume":"55","author":"Kusumi","year":"2001","journal-title":"Psychiatry Clin Neurosci"},{"key":"R87-20230911","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.nmd.2007.01.020","article-title":"Hypokalaemic periodic paralysis due to the CACNA1S R1239H mutation in a large african family.","volume":"17","author":"Houinato","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"R88-20230911","doi-asserted-by":"crossref","first-page":"218","DOI":"10.4103\/JPN.JPN_44_17","article-title":"Phenotypical variation with same genetic mutation in familial hypokalemic periodic paralysis.","volume":"13","author":"Kumar","year":"2018","journal-title":"J Pediatr Neurosci"},{"key":"R89-20230911","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12031-011-9596-1","article-title":"A novel mutation in CACNA1S gene associated with hypokalemic periodic paralysis which has a gender difference in the penetrance.","volume":"46","author":"Li","year":"2012","journal-title":"J Mol Neurosci"},{"key":"R90-20230911","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1007\/s00467-017-3755-8","article-title":"Exome sequencing in jewish and arab patients with rhabdomyolysis reveals single-gene etiology in 43% of cases.","volume":"32","author":"Vivante","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"R91-20230911","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/ene.13528","article-title":"Rhabdomyolysis and fluctuating asymptomatic hyperckemia associated with CACNA1S variant.","volume":"25","author":"Anandan","year":"2018","journal-title":"Eur J Neurol"},{"key":"R92-20230911","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1210\/jc.2003-030924","article-title":"Association of novel single nucleotide polymorphisms in the calcium channel alpha 1 subunit gene (ca(v)1.1) and thyrotoxic periodic paralysis.","volume":"89","author":"Kung","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R93-20230911","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2265.2006.02713.x","article-title":"The alpha(1S) subunit of the L-type calcium channel is not a predisposition gene for thyrotoxic periodic paralysis.","volume":"66","author":"Tang","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R94-20230911","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/105072504773297858","article-title":"Absence of ion channels CACN1AS and SCN4A mutations in thyrotoxic hypokalemic periodic paralysis.","volume":"14","author":"Ng","year":"2004","journal-title":"Thyroid"},{"key":"R95-20230911","first-page":"274","article-title":"Thyrotoxic periodic paralysis: clinical and molecular aspects.","volume":"43","author":"Falhammar","year":"2013","journal-title":"Endocrine"},{"key":"R96-20230911","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000070191","article-title":"Clinical and molecular analysis of Chinese patients with thyrotoxic periodic paralysis.","volume":"49","author":"Chen","year":"2003","journal-title":"Eur Neurol"},{"key":"R97-20230911","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1177\/0004563218785395","article-title":"Does thyrotoxic periodic paralysis have a genetic predisposition? A case report.","volume":"55","author":"Rasheed","year":"2018","journal-title":"Ann Clin Biochem"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T05:16:19Z","timestamp":1694409379000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000393","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}